Europe Point of Care Diagnostics Market

The Europe PoC diagnostics market is expected to witness a CAGR of 10.0% during the forecast period, fueled by the rising prevalence of infectious and cancer diseases in the region. The need for point-of-care diagnostics is also on the rise due to the need for decentralized testing, especially in hospitals. In addition, the government initiatives for the diagnosis and treatment of diseases are also driving the market. The European point-of-care diagnostics market is expected to grow from USD 4.45 billion in 2026 to USD 7.17 billion in 2031.

The Europe PoC diagnostics market is fueled by the presence of various global and local key players, such as Siemens Healthineers (Germany),  Abbott (US), Danaher Corporation (US), F. Hoffmann Roche (Switzerland), bioMérieux (France), Thermo (US), BD (US), BIOSYNEX (France), EKF Diagnostics (UK), Nova (US), Trinity (Ireland), Werfen SA (Spain), Boditech Med (South Korea), and SEKISUI, among others. These companies are actively trying to make their presence in the European market by adopting different approaches, such as the development of technologically advanced point-of-care products, collaborations, agreements, partnerships, geographical expansion, mergers, and acquisitions, with a focus on the development of innovative and quick PoC testing solutions.

To know about the assumptions considered for the study download the pdf brochure

In December 2025, Roche announced that its point-of-care PCR test for Bordetella has been granted CE IVDR certification in Europe and FDA clearance. The test provides reliable results in 15 minutes and is designed for use in general practitioner practices and emergency rooms. In January 2025, bioMérieux broadened its point-of-care diagnostics offering by acquiring Norwegian company SpinChip Diagnostics ASA. The rapid immunoassay technology developed by SpinChip enables blood test results in less than 10 minutes. This acquisition is expected to complement bioMérieux’s existing molecular point-of-care offerings, such as BIOFIRE SPOTFIRE, by adding high-sensitivity immunoassays for acute care biomarkers.

Abbott is one of the major participants in the European point-of-care diagnostics market, and this is due to its strong portfolio of diagnostic systems, which include blood screening, immunoassay, and clinical chemistry solutions. The strong geographical reach of the company across Europe has made it possible for the company to adopt its point-of-care solutions in hospitals, clinics, and other decentralized settings. Abbott is able to maintain its position in the market through its strong focus on innovation and continuous new product launches, along with timely approvals from regulatory authorities.

Siemens Healthineers has a robust, established presence in the European point-of-care diagnostics market, thanks to its long-standing leadership position in the broader diagnostics market. The company’s diversified product offerings and strong geographical reach in Europe have helped it sustain a competitive edge in the market. The company’s established direct and indirect distribution channels facilitate smooth distribution and adoption of point-of-care solutions to cater to the growing demands in the clinical field. Moreover, Siemens Healthineers’ prudent strategy of pursuing growth through innovation and acquisitions has further strengthened its established position in the European point-of-care diagnostics market.

Market Ranking

The Europe point-of-care market is led by key manufacturers such as Siemens Healthineers (Germany), Danaher (US), Abbott Diagnostics (US), Roche Ltd (Switzerland), and Becton Dickinson and Company (US), which are well-known for their extensive point-of-care testing product lines and technological advancements. Abbott has created a strong presence in the European market for its extensive range of PoC tests and near-patient testing solutions, which are well-suited for PoC testing. Siemens and Roche Ltd maintain a competitive edge in the market with their extensive point-of-care testing product lines that facilitate fast and accurate testing results for critical and routine testing. Danaher uses its diagnostic knowledge to meet the increasing need for rapid and accurate point-of-care testing solutions in Europe, while BD contributes to the market with point-of-care solutions that are designed to improve workflow efficiency and patient safety. These companies have been instrumental in the increasing adoption of point-of-care diagnostics in the European healthcare environment.

Related Reports:

Europe Point of Care Diagnostics Market by Product [Glucose, Infectious Disease (TB, HAI, STD), Pregnancy], Purchase Mode (Rx, OTC), Technology [Biochemistry, MDx (RT-PCR, INAAT)], Sample (Blood, Urine), End User (Home Care, Hospitals) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com